Impiricus

Impiricus operates an AI-powered HCP Engagement Engine that delivers evidence-based pharmaceutical resources directly to healthcare professionals over real-time messaging channels. The company's technical work spans artificial intelligence and machine learning, real-time communication infrastructure, engagement and messaging analytics, and the management of opt-in HCP data networks. Its stated aim is to cut through the noise in the exchange between physicians and pharmaceutical companies.

The HCP Engagement Engine connects opted-in healthcare professionals with pharmaceutical content; the company reports that 95% of messages are opened within three minutes. Its Opted-in HCP Network is described as the largest such network of healthcare providers and reaches roughly 30% of physicians who do not engage through traditional channels. In 2025, Impiricus reports that one million patients were helped in accessing therapy. The company ranked first on the Deloitte 2025 Technology Fast 500 as the fastest-growing company in North America and operates across North America, with activity in pharmaceuticals, life sciences, dermatology and patient therapy access.

Impiricus was founded by a board-certified dermatologist and a healthcare executive, and grew out of frustration with existing pharma-to-HCP engagement. The company describes its approach as physician-centric, with an emphasis on underserved healthcare professionals, equitable access to evidence-based resources, and patient outcomes.